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Abstract The sorting of soluble proteins into the regulated
secretory pathway (RSP) involves aggregation, but whether an
additional sorting domain is also required is not clear. By fusing
vasopressin prohormone (proVP) fragments to green fluorescent
protein (eGFP) we have determined whether a sorting domain
can function independently of the aggregative neurophysin
domain. Although eGFP itself can be immunolocalised in the
RSP of Neuro2A and AtT20 cells, most of the protein enters the
constitutive pathway, and is found in the culture medium. In
contrast, the N-terminal 27 residues of proVP promote residence
in the RSP. Furthermore, only the processed form of this fusion
was secreted when stimulated. We suggest a sorting mechanism
based on the recognition of a sorting motif, the efficiency of
which is enhanced by neurophysin aggregation. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The tra⁄cking of secretory proteins through the regulated
secretory pathway (RSP) has been studied extensively during
the last decade (reviewed in [1,2]), but a satisfactory descrip-
tion of the sorting mechanism remains elusive. Regulated se-
cretory proteins aggregate once they encounter the acidic mi-
lieu of the trans-Golgi network (TGN). This is inherent in
many, if not all, regulated secretory proteins. Once aggre-
gated, the secretory proteins form a dense core characteristic
of secretory vesicles of the RSP. It might be that the aggregate
is enough to induce granule formation, as proposed in the
sorting-by-retention hypothesis [1]. Further exclusion of
non-regulated secretory proteins is achieved during matura-
tion of the dense core granule in which the non-aggregative,
soluble proteins are diverted into the constitutive secretory
pathway. Importantly, this model allows for the entry of
non-regulated secretory proteins into the RSP, and does not
require association with a sorting receptor or the secretory
granule membrane. On the other hand it might be that the
aggregate, once formed, or during formation in the TGN, is
being recognised by sorting receptors for entry into the regu-
lated secretory vesicle [3]. The nature of sorting domains is
still unclear, since all the sorting domains found so far do not
display an obvious similarity. How aggregation is regulated
intra- or intermolecularly is only clear in the case of the vaso-
pressin (VP) prohormone. This gives an opportunity to study
the presence of a sorting domain separate from the aggrega-
tion, which relies on an intact VP prohormone.
The VP prohormone consists of three domains: the non-
apeptide hormone VP, neurophysin (NP, 93 residues) and a
C-terminal glycopeptide (GP, 39 residues) (Fig. 1). This pro-
hormone is closely related to the oxytocin (OT) prohormone
which looks identical in organisation, having a hormone do-
main and a NP domain, but not a GP domain. The OT
hormone only di¡ers in two amino acids and the OT-associ-
ated NP domain is 96% identical to VP-associated NP [4]. NP
has the capacity to oligomerise into dimers and high-order
complexes and this is greatly facilitated by hormone associa-
tion to NP (reviewed in [5]). These properties of NP are es-
pecially favoured by TGN conditions. Therefore, prohormone
aggregation is either under the control of the hormone bind-
ing or directly triggered by encountering the TGN milieu. In
fact, the hormone binding takes place in the endoplasmic
reticulum (ER), where the folding of the prohormone and
the correct disul¢de linkage pattern (of eight disul¢des) is
safeguarded by the hormone^NP binding [6,7]. It has been
proposed recently that the hormone domain acts as an inter-
nal chaperone for the folding of the whole prohormone [8].
Following on from this, it appears that the aggregation of NP
in the secretory pathway is solely regulated by the solvent
conditions in the TGN. Thus, we reasoned it may be possible,
for the ¢rst time, to dissect aggregation from a putative sort-
ing-by-recognition mechanism by fusing truncated fragments
of VP prohormone to a £uorescent tag (the enhanced form of
green £uorescent protein, eGFP) which can be followed
through the secretory pathway. Therefore, we fused eGFP
to various truncated VP prohormone fragments, in which re-
gions of the NP domain were eliminated (Fig. 1). We found
that sorting was achieved by only a small N-terminal domain
of the VP prohormone of 27 amino acids.
2. Materials and methods
2.1. Constructs
Fusions of N-terminal fragments of the VP preprohormone with
eGFP were generated. The cDNAs encoding the wild-type rat VP
preprohormone (pWT-cDNA/AmpI) or the preprohormone in which
the VP domain is deleted (pvVP-cDNA/AmpI) were inserted into the
EcoRV site of pcDNA/AmpI (Invitrogen) [9,10]. Deletion fragments
were generated from these constructs using di¡erent restriction sites
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and inserted in frame with the eGFP coding sequence in pEGFP-N1
(Clontech). The following fusion plasmids were generated: (a)
pVP121-eGFP-N1, a HindIII-SmaI fragment of the preproVP
cDNA was inserted into the corresponding sites of pEGFP-N1. The
corresponding fusion is called VP121-eGFP; (b) pVP27-eGFP-N1, a
HindIII-BglI fragment of the preproVP cDNA was inserted into a
HindIII-PstI-digested pEGFP-N1, where the BglI and PstI ends
were blunt-ligated. The corresponding fusion is called VP27-eGFP;
(c) pVP10-GFP-N1, a HindIII-FokI fragment of the preproVP cDNA
was inserted into a HindIII-AccI-digested pEGFP-N1, where the FokI
and AccI ends were blunt-ligated. The corresponding fusion is called
VP10-eGFP; (d) p(vVP)NP15-GFP-N1, a HindIII-BglI fragment of
pvVP-cDNA/AmpI was inserted into a HindIII-PstI-digested pEGFP-
N1, where the BglI and PstI ends were blunt-ligated. The correspond-
ing fusion is called [vVP]NP15-eGFP. All generated fusions were
checked by sequencing.
2.2. Cell culture and transfection
Mouse Neuro2A neuroblastoma cells and mouse anterior pituitary
AtT20 cells (kindly provided by Prof. J.P.H. Burbach, Utrecht, The
Netherlands) were cultured with Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% (v/v) foetal bovine serum, non-es-
sential amino acids and 200 IU/ml pentamycin/streptomycin (medium
and all supplements from Life Technologies). Cells were transfected
by calcium precipitation [11] or liposome-mediated transfection using
Escort1 (Sigma) or Fugene6 (Roche Molecular Biochemical). After
transfection, cells were either analysed over the following 2 or 3 days
or further selected for stable expression with 500 Wg/ml gentamicin
(G418, Life Technologies).
2.3. Immuno£uorescence microscopy
Cells were plated onto 22 mm diameter glass coverslips and ¢xed
with 4% (w/v) paraformaldehyde at a density of approximately 70%.
For immunostaining, the cells were ¢rst permeabilised with 0.1% (v/v)
Triton X-100 for 4 min, then subjected to a 1 h incubation at room
temperature with 1% (w/v) bovine serum albumin in phosphate-bu¡-
ered saline (PBS, pH 7.4) and then incubated for 2 h at room temper-
ature with primary antibody: anti-chromogranin (Research Diagnos-
tics Inc.), then washed with PBS and further incubated for another 2 h
at room temperature with secondary antibody: TRITC-labelled anti-
rabbit antibody (Vector Laboratories). After several washes with PBS,
stained cells were embedded in Vectashield (Vector Laboratories) and
analysed using a Leitz confocal laser scanning microscope and anal-
ysis software package.
2.4. Immunoprecipitation
Cells were treated and analysed as described previously [12]. In
short, cells were labelled overnight for 16^18 h with 2.5 Wl (0.74
MBq) [35S]Met or [35S]Cys (ICN Biochemicals). To assess the
steady-state distribution of a fusion, the cells and media were har-
vested directly after the overnight labelling and immunoprecipitated
as described [12]. To measure regulated secretion, the cells were
washed twice with PBS and subsequently incubated in either basal
secretion medium containing 125 mM NaCl, 4.8 mM KCl, 1.8 mM
CaCl2, 1.4 MgCl2, 10 mM glucose, 25 mM HEPES (pH 7.4), or
stimulus secretion medium which is basal secretion medium with
CaCl2 replaced by 3 mM BaCl2. After 10 min incubation at 37‡C
in a CO2 incubator (5% v/v CO2) cells and medium were harvested
and immunoprecipitated as described [12] with the only di¡erences
that the following primary antibodies were used: 1:500 anti-NP
(ICN Biochemicals) or 1:500 anti-GFP polyclonal (Clontech), and
that in case of the GFP immunoprecipitation the protein A Sepharose
beads were washed four times with lysis bu¡er containing 0.1% (v/v)
Triton X-100.
2.5. Western blotting and secretion experiments
Cells were plated as for immunoprecipitation. For secretion, cells
were grown to a density of 80%, washed two times with PBS and
subjected to either 1 ml/well basal secretion medium (as above) or
1 ml/well stimulus secretion medium (as above). The secretion media
were dialysed against 2 l of distilled H2O overnight at 4‡C and sub-
sequently dried in vacuo using a Speedvac (Savant). For analysis, cell
and medium pellets were boiled in Tris^glycine sample bu¡er and
loaded onto a 13.5 or 15% (w/v) SDS^PAGE Tris^glycine (pH 8.8)
gel system and transferred onto Immobilon-P transfer membranes
(Millipore). After transfer the blots were equilibrated in TBST (20
mM Tris^HCl (pH 7.4), 137 mM NaCl, 0.1% (v/v) Triton X-100)
for 15 min and then blocked with TBSAT (5% (w/v) BSA in TBST)
for 1 h at room temperature. Subsequently, the blots were incubated
for 1 h at room temperature in TBSAT with primary antibody: anti-
eGFP (Living Colors Peptide antibody, Clontech) or anti-VP (86/3-F,
kindly given by Sonia Birkett) [13]. The blots were washed several
times in TBST and subsequently incubated with a horseradish peroxi-
dase-linked anti-rabbit antibody (Amersham) in TBSAT for 1 h at
room temperature. The blots were washed again several times in
TBST and ¢nally the blots were incubated with a 1:1 mixture of
ECL reagents 1 and 2 (ECL kit from Amersham, RPN2109) for ex-
actly 1 min at room temperature. Several exposures were taken from
the blots and the ¢lms were developed and analysed.
3. Results
3.1. Introducing eGFP into the secretory pathway
Native GFP is a cytosolic protein in jelly¢sh (Aequorea
victoria) and when the enhanced form (eGFP) is expressed
in eukaryotic cell lines it also accumulates in the cytosol
(Fig. 2) [14,15]. GFP has been fused with several targeting
sequences recently to show that cellular location is not af-
fected by the eGFP tag [17,18]. However, eGFP might be
targeted to any organelle within the secretory pathway by
cryptic sequences. Therefore, eGFP was fused with the signal
peptide of the VP preprohormone (SP-eGFP). The signal pep-
tide will deliver eGFP into the ER and since proper cleavage
of the signal peptide is directed by the structural information
within the signal peptide itself [16], eGFP would be able to
follow its own route through the secretory pathway. After
heterologous expression in the neuroendocrine Neuro2A and
AtT20 cell lines, immunolocalisation revealed green £uores-
Fig. 1. Schematic overview of the various eGFP fusions. Shown are
all the fusions used in this study compared with the wild-type VP
preprohormone with the signal peptide as a striped bar, the VP do-
main in white, the NP domain in dotted, and the GP domain in
grey. The number after the fragment name ‘VP’ indicates the num-
ber of N-terminal proVP residues, whereas the number after the
fragment name ‘NP’ indicates the number of N-terminal NP resi-
dues.
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cent granules that colocalised with chromogranin, an estab-
lished soluble marker of the RSP (Fig. 2). Since immunolo-
calisation only allows the observation of the intracellular por-
tion of a secretory protein it was necessary to analyse the
distribution of eGFP inside and outside SP-eGFP-expressing
cells by immunoprecipitation. This demonstrated that after an
overnight labelling, which can be regarded as an assessment of
the steady-state distribution, eGFP introduced into the secre-
tory pathway is mainly found outside the cell in the culture
medium (Fig. 2). Only 20^26% of eGFP expressed as SP-
eGFP was retained inside Neuro2A and AtT20 cells. The
remaining 74^80% was released into the culture medium,
which is typical of a predominantly constitutively secreted
protein. A constitutive secretory protein (ovalbumin) was sim-
ilarly distributed in the cell and medium (data not shown).
3.2. Heterologous expression of eGFP fused to truncated
fragments of proVP
To address the question of whether a regulated secretory
protein like proVP harbours a sorting signal for delivery into
Fig. 2. Heterologous expression of SP-eGFP. Expression of eGFP in Neuro2A cells shows expression in the cytosol (A). SP-eGFP expressed in
Neuro2A (B) and AtT20 (C) cells is detected in a granular fashion and colocalised with red anti-chromogranin staining. When cell and culture
medium were analysed by immunoprecipitation using a polyclonal anti-GFP antiserum eGFP was predominantly found in the culture medium
after overnight labelling (histogram).
C
Fig. 3. Distribution of VP-eGFP fusions over cell and medium.
Shown is the result of immunoprecipitation analysis after overnight
labelling of cell (striped) and culture medium (white) of Neuro2A
and AtT20 cells expressing the di¡erent VP-eGFP fusions, which
are abbreviated to their respective VP domains fused to eGFP (SP,
VP27, VP10, [vVP]NP15). In AtT20 cells the VP27-eGFP fusion
was also found as a smaller, processed form (proc. VP27). Statistical
analysis was performed using ANOVA or Student’s t-test (P6 0.05).
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the RSP, various fusions with eGFP were constructed (Fig. 1).
Immunolocalisation of all fusions looked identical with regard
to their colocalisation with chromogranin and identical to SP-
eGFP as shown in Fig. 2B,C. However, as demonstrated with
the SP-eGFP fusion, this does not necessarily indicate sorting
into the RSP. Further analysis by immunoprecipitation of the
relative distribution of steady-state eGFP levels in the cell and
in medium revealed that the fusions VP10-eGFP (VP domain
fused to eGFP) and [vVP]NP15-eGFP were mainly released
into the culture medium similar to SP-eGFP (Fig. 3). In con-
trast, two fusions were found more inside the cell ^ VP121-
eGFP and VP27-eGFP (Figs. 3 and 4). The fusion VP121-
eGFP is the longest fusion used in this study, and incorpo-
rates the VP domain, the NP domain and 14 residues of the
C-terminal glycopeptide (Fig. 1). Immunoprecipitation with
an anti-NP antiserum demonstrated the presence of fully
processed NP, identical to that of the wild-type VP prohor-
mone (Fig. 4). More importantly, the shorter fusion VP27-
eGFP, consisting of the VP domain and the ¢rst 14 residues
of the NP domain, is also mainly localised inside the cell (Fig.
3). In addition, in AtT20 cells, VP27-eGFP is found to be
processed into two forms: one form migrating at the same
level as (SDS^PAGE) or slightly above (Tris^Tricine^
PAGE) standard eGFP, and one form migrating at approx-
imately 30 kDa, corresponding to the size of the full-length
fusion, and with the single eGFP-immunoreactive form de-
tected in Neuro2A cells (Fig. 5). These two bands were always
detected in AtT20 cells whether heterologous or homologous
stable cell lines were analysed. These data suggest a higher
e⁄ciency of processing in AtT20 cells compared to Neuro2A
cells and, indeed, the prohormone convertases PC1/3 and
PC2, which are regarded as the main candidates for cleaving
the dibasic site between VP and NP in the VP prohormone,
are expressed abundantly in AtT20 cells, but are virtually
absent in Neuro2A cells [17,18]. Probing with an antibody
recognising VP further con¢rmed that only the upper band
contains the VP domain, whereas the lower band was not
detected (Fig. 5). Analysis of the distribution of the two forms
over cell and medium showed that the full-length fusion was
released in a constitutive fashion whereas the processed form
was retained in the cell (Fig. 3). To assess whether the pro-
cessed form was secreted in a regulated fashion, a secretion
stimulus was applied for 10 min and secretion of eGFP-
and VP-related forms were measured by Western blotting
(Fig. 6). Our secretion paradigm proves to be an adequate
model to compare the secretion of di¡erent fusions, because
the secretion of NP derived from wild-type VP prohormone is
released e¡ectively by this paradigm (Fig. 6A). Furthermore,
the fact that AtT20 cells harbour predominantly the fully
processed NP after overnight labelling indicates strongly
that there is an e⁄cient sorting and storage of VP prohor-
mone (product). When this paradigm is applied to SP-eGFP-
expressing AtT20 cells, there is a small amount of stimulated
release (Fig. 6B), but more importantly, when applied to
VP27-eGFP-expressing AtT20 cells, there is almost exclusively
release of the processed fusion (Fig. 6C).
These data con¢rm that the unprocessed form of VP27-
Fig. 4. Expression and distribution of VP121-eGFP over cell and
medium. Distribution over cell and medium of VP121-eGFP in
AtT20 cells (C) and culture medium (M) was assessed by immuno-
precipitation. Using an anti-NP antiserum (KNP) one band corre-
sponding to NP is found inside the cell of wild-type prohormone-ex-
pressing cells (WT), whereas three bands are found in the culture
medium corresponding to prohormone, partially processed VP-NP
and fully processed NP. These bands were identi¢ed as such earlier
[12]. In VP121-eGFP-expressing cells a similar pattern is found with
the anti-NP antiserum, but in addition also a band corresponding
to the full-length fusion (43 kDa) is detected at 45 kDa which is
also detected by an anti-eGFP antiserum (KGFP). The band run-
ning at around 16.9 kDa corresponds to the shorter VP-NP-GP1ÿ14
(17 kDa). The anti-eGFP antiserum detected at least three bands in
cell and medium of which the ¢rst one corresponds to the full-
length fusion (45 kDa), the second one corresponds to GP1ÿ14-
eGFP (33 kDa) and the third one corresponds to eGFP (26 kDa).
Fig. 5. Processing of VP27-eGFP in AtT20 cells. The top panel
shows processing of VP27-eGFP in AtT20 cells (AtT, lanes 1^4),
but not in Neuro2A cells (N2A, lanes 5^6). In both cell (C) and
medium (M) two bands are immunoprecipitated with an anti-GFP
antiserum (KGFP) in VP27-eGFP-expressing AtT20 cells (VP27,
lanes 3^4), whereas in VP27-eGFP-expressing Neuro2A cells (VP27,
lanes 5^6) only one band appears corresponding to 31 kDa, the ex-
pected size of the full-length fusion. Control cells and medium of
normal AtT20 cells do not show any immunoreactive bands (con,
lanes 1^2). In the bottom panel Western blotting analysis of VP27-
eGFP-expressing AtT20 cells shows that an anti-GFP antiserum
(lane 1) detected two bands, whereas an anti-VP antiserum (KVP)
detected only the upper band corresponding to the full-length fu-
sion. The third lane shows the non-speci¢c bands found with anti-
VP antiserum in control AtT20 cells (con). Equal amounts of all
cell samples were loaded onto gel for the Western blot: the equiva-
lent of 10% of cells from a 3.5 cm well (6 well plate).
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eGFP is predominantly directed to the constitutive pathway,
whereas the processed VP27-eGFP form is targeted to the
regulated secretory pathway.
4. Discussion
We have demonstrated that a short linear signal from a
prohormone can direct the sorting of a heterologous protein
into the RSP.
We were initially surprised to ¢nd that the non-secretory
protein like eGFP could be found in the RSP, once directed
into the ER by a signal peptide. GFP/enhanced GFP has been
used several times in sorting studies, but it has never been
shown how it travels through the secretory pathway on its
own. Since 80% of the signal peptide-eGFP was found outside
the cell, there appears to be no problem with the tra⁄cking of
the signal peptide-eGFP fusion. Relying on immunoprecipita-
tion data alone we simply would have concluded that the
signal peptide-eGFP fusion behaves like a constitutively se-
creted protein. However, the strong £uorescence of eGFP
made it possible to localise it in granules of the RSP as
well. Thus, regarding the immunoprecipitation data, this in-
dicates that a small proportion of the expressed signal pep-
tide-eGFP is found in the RSP. Since such an analysis has not
been carried out before it adds two important ¢ndings to the
knowledge about sorting into the RSP: (1) eGFP behaves like
a constitutively secreted protein and is therefore a legitimate
marker protein for any study relating to the tra⁄cking
through the secretory pathway starting from the ER; (2)
more importantly, a non-secretory protein can ine⁄ciently
enter the RSP, most likely through leakage as proposed by
Arvan and Castle [1]. Their sorting-by-retention hypothesis
allows for ‘leakage’ of non-regulated secretory proteins into
the RSP which does not require any recognition process dur-
ing sorting [1].
However, we went on to show that fusions of regions of the
VP prohormone with eGFP could result in a higher extent of
sorting. Leaving the NP domain intact results in full process-
ing of the prohormone, as demonstrated by the analysis of the
fusion VP121-eGFP, whereas partial or complete deletion of
the NP domain leads to incomplete processing and sorting, or
even missorting. Only the processed derivative of fusion
VP27-eGFP was retained in the RSP.
Since only VP27-eGFP was found to be sorted into the RSP
and not the separate domains of the VP27 fragment (VP10
and [vVP]NP15 fused to eGFP), we have demonstrated that it
is crucial to have both the VP domain and the N-terminus of
the NP domain to achieve sorting. This could mean that the
enzymes that recognise the processing site between VP and
NP (Fig. 1) are involved in sorting. However, VP27-eGFP is
still sorted into the RSP of Neuro2A cells, which virtually
lack prohormone convertases. It is unlikely, therefore, that
the prohormone convertases are involved in speci¢c retention.
The explanation for the exclusive sorting of VP27-eGFP only
may be found in the ample knowledge of the physicochemical
properties of the VP precursor. In the crystal structures of the
hormone^NP complexes, the N-terminal portion of NP is dis-
ordered, without a de¢ned structure. However, when analysed
in the prohormone setting, with the N-terminal portion of NP
covalently linked to the hormone, it retains a de¢ned second-
ary structure [19,20]. Therefore, only in the prohormone set-
ting, as in VP27-GFP, can the N-terminus of NP (residues 1^
15) retain a speci¢c structure, which could be required for
sorting-recognition.
Taking the processing in AtT20 cells as a measure of sort-
ing into the RSP, it appears that only a relatively small pro-
portion of the VP27-eGFP fusion is sorted and processed,
suggesting that the mechanism of sorting by recognition is,
on its own, rather ine⁄cient. Since we have shown that sort-
ing by recognition is utilised as a means to retain a prohor-
mone inside the regulated secretory granules, it is likely that
adding the aggregative property to this would increase the
retention of the prohormone to required e⁄ciency. Only the
vast structural and physicochemical knowledge of the VP/OT
precursor (domains) [4,5] and previous work [6,10,12] makes it
possible to dissect the aggregative and sorting properties of
this prohormone.
In summary, we have identi¢ed a sorting domain in the VP
prohormone, which resides within the N-terminal 27 residues.
Physicochemical data indicate that it is largely located on the
Fig. 6. Regulated secretion of wild-type VP prohormone, SP-eGFP
and VP27-eGFP. A: Wild-type VP prohormone-expressing AtT20
cells (C) and medium (M) were analysed for the steady-state distri-
bution of NP-related prohormone material (StSt, lanes 3^4) and
regulated secretion (lanes 5^6 = basal release, lanes 7^8 = stimulated
release) and compared to normal, control AtT20 cells (lanes 1^2,
con) as assessed by immunoprecipitation with an anti-NP antiserum.
For the secretion protocol see Section 2. B: The regulated secretion
of SP-eGFP-expressing AtT20 cells was analysed by Western blot-
ting using an anti-GFP antiserum. The same secretion protocol was
used as in A for basal (bas, lane 2) and stimulated (stim, lane 3) re-
lease. As a control is shown the intracellular content (lane 1, cell)
and the migration position of standard GFP (GFP, lane 4). C: The
regulated secretion of VP27-eGFP fusion was analysed identical to
the SP-eGFP fusion analysis in A and B, where ‘cell’ is the intracel-
lular content, ‘bas’ is basal release, ‘stim’ is stimulated release and
‘GFP’ indicates the migration position of standard GFP as assessed
by Western blotting using an anti-GFP antiserum. Under each lane
of the Western blots in B and C is indicated in percentages how
much of each sample was loaded.
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surface of the prohormone. This study shows, for the ¢rst
time, that sorting by recognition, on its own, is an ine⁄cient
mechanism of sorting and also for the ¢rst time, that sorting
by retention can cause visible leakage of non-secretory pro-
teins into the RSP as anticipated [1]. Our data suggest that a
combinatorial mechanism of aggregate sorting by recognition
and sorting by retention is responsible for a complete, e⁄cient
sorting into the RSP.
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